Home

Genetic architecture and resulting phenotype

 

The Navarini Lab uses a two-pronged approach of analysing genetic and visual data to understand skin conditions.

 

This page aims to inform and update you about our activities. If you have similar interests, we are always looking for collaborations. Also, the page is a home for the reference assistant that we consider a significant advance for scientific writing - why don't you try it yourself?

 

Utilizing exome-wide next generation sequencing allows us to detect disease driving genetic alterations. These are then taken forward for functional analysis, which sometimes can lead to novel therapeutic approaches. Our main focus of conditions are the neutrophil-mediated inflammatory diseases (NMID) including pustular psoriasis, pyoderma gangrenosum, Sweet syndrome and others. Other projects include additional immune-mediated conditions.

 

Our Vision-Team also seeks to extract objective insights out of imaging, which are the dermatologists' most valuable data. We use systematic evaluation of common skin conditions with new visual tools such as dermoscopy as well as machine-learning techniques that enabled us to develop eczema-detecting algorithms.

 

With these two central themes, we aim towards optimised genotype-phenotype correlations and clinical insights that could be useful for future decision support systems.

 

 

Recent Posts

 

  • Submitted patent for new antiviral formulation against SARS-CoV-2 (June 2020)

 

  • Submitted patent for antipruritic formulation (March 2020)

 

  • Prof. Navarini to speak at the largest Artificial Intelligence meeting in the world (Basel, September 2019)

 

  • This year, we will host the Swiss National Clinical Dermatology and Venerology Meeting here in Basel (September 2019)

 

  • We have installed and started full body imaging with the Canfield WB360 device that uses 92 cameras to create a high-resolution 3D picture of the patient (July 2019)

 

  • The novel Kleresca device with biophotons is now in our large choice of treatment options (July 2019)

 

  • Our Nature Immunology paper together with the Hess and Recher group was just accepted (June 2019)

 

  • Our analysis of smoking and efficacy of systemic treatments in psoriasis accepted in Acta Dermato-Venereologica (June 2019)

 

  • Rishika Agarwal has joined the laboratory and will soon be starting her PhD thesis (June 2019)

 

  • Prof. Navarini was elected in the editorial board of the Journal of the European Association of Dermatology and Venereology (March 2019)

 

  • The Skin Module of the Swiss ETH Medicine Bachelor Studies designed by Prof. Navarini and Prof. Detmar took place and was a great success (May 2019)

 

  • Our electronic dermatology handbook Dermakonsil is now supported by Karger publisher (May 2019)

 

  • Prof. Navarini was elected board member of the European Dermatology Foundation (February 2019)